Qiagen Past Earnings Performance

Past criteria checks 2/6

Qiagen has been growing earnings at an average annual rate of 30.4%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 7.7% per year. Qiagen's return on equity is 9%, and it has net margins of 17.4%.

Key information

30.4%

Earnings growth rate

30.4%

EPS growth rate

Life Sciences Industry Growth21.5%
Revenue growth rate7.7%
Return on equity9.0%
Net Margin17.4%
Next Earnings Update29 Apr 2024

Recent past performance updates

Recent updates

Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly

Mar 20
Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly

Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)

Feb 13
Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings

Jan 23
Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings

These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well

Dec 08
These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued

Oct 24
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued

Qiagen: No Upsides Slated In FY'23 In Core Business Lines, Reiterate Hold

Sep 09

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Sep 04
Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Jul 17
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen: Major Asset Growth Needed In Post-Covid World

Jun 22

Is Qiagen (NYSE:QGEN) Using Too Much Debt?

May 23
Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Apr 18
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Feb 15
Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Qiagen: Strong Q4, Derisked Portfolio, Fairly Valued

Feb 14

Qiagen Non-GAAP EPS of $0.53, revenue of $498M, FY23 guidance initiated

Feb 07

If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity

Jan 18
If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity

Qiagen, Helix partner to advance NGS companion diagnostics in hereditary diseases

Jan 06

A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Jan 04
A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen's test gets FDA nod for companion diagnostic to Mirati's cancer drug Krazati

Dec 13

Qiagen Non-GAAP EPS of $0.53 beats by $0.08, revenue of $500M beats by $17.91M

Nov 07

We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt

Oct 31
We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt

Qiagen stock down after BHF downgrades rating to Neutral

Oct 10

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Oct 04
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen to develop companion diagnostic for Neuron23's Parkinson's disease drug candidate

Sep 14

Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

Aug 25
Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Jul 28
Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Qiagen Fails To Justify Inclusion In Long-Biased, Balanced Macro Portfolio

Jul 15

Is Qiagen N.V. (NYSE:QGEN) Trading At A 36% Discount?

Jun 29
Is Qiagen N.V. (NYSE:QGEN) Trading At A 36% Discount?

Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

May 26
Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

Is Qiagen (NYSE:QGEN) A Risky Investment?

Apr 29
Is Qiagen (NYSE:QGEN) A Risky Investment?

Are Investors Undervaluing QIAGEN N.V. (NYSE:QGEN) By 31%?

Mar 30
Are Investors Undervaluing QIAGEN N.V. (NYSE:QGEN) By 31%?

Revenue & Expenses Breakdown
Beta

How Qiagen makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NYSE:QGEN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 231,965341579199
30 Sep 231,956485600188
30 Jun 231,979490606189
31 Mar 232,000505612189
31 Dec 222,142423604190
30 Sep 222,226488618178
30 Jun 222,261539616177
31 Mar 222,313563606180
31 Dec 212,252513584190
30 Sep 212,240311604184
30 Jun 212,190480572182
31 Mar 212,065449549162
31 Dec 201,870359525149
30 Sep 201,713191522137
30 Jun 201,61214517142
31 Mar 201,550-31530151
31 Dec 191,526-41530157
30 Sep 191,516-25502164
30 Jun 191,511196492164
31 Mar 191,507188508163
31 Dec 181,502190497162
30 Sep 181,49690476162
30 Jun 181,48278474158
31 Mar 181,45355466157
31 Dec 171,41840478154
30 Sep 171,38789467145
30 Jun 171,36275480143
31 Mar 171,34782480147
31 Dec 161,33880470150
30 Sep 161,320123485157
30 Jun 161,296123471157
31 Mar 161,281126450148
31 Dec 151,281130445147
30 Sep 151,293104475151
30 Jun 151,315105484157
31 Mar 151,326113487162
31 Dec 141,345116490164
30 Sep 141,345151487163
30 Jun 141,331157487156
31 Mar 141,31572487152
31 Dec 131,30269486146
30 Sep 131,28744498112
30 Jun 131,27032512108

Quality Earnings: QGEN has high quality earnings.

Growing Profit Margin: QGEN's current net profit margins (17.4%) are lower than last year (19.8%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: QGEN's earnings have grown significantly by 30.4% per year over the past 5 years.

Accelerating Growth: QGEN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: QGEN had negative earnings growth (-19.4%) over the past year, making it difficult to compare to the Life Sciences industry average (-9.3%).


Return on Equity

High ROE: QGEN's Return on Equity (9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.